financetom
Business
financetom
/
Business
/
Travel + Leisure Q2 Adjusted Earnings, Net Revenue Rise; Offers Q3, Full Year Adjusted EBITDA Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Travel + Leisure Q2 Adjusted Earnings, Net Revenue Rise; Offers Q3, Full Year Adjusted EBITDA Guidance
Jul 24, 2024 4:34 AM

07:02 AM EDT, 07/24/2024 (MT Newswires) -- Travel + Leisure ( TNL ) reported Q2 adjusted earnings Wednesday of $1.52 per diluted share, up from $1.33 a year earlier.

Analysts polled by Capital IQ expected $1.41.

Net revenue for the quarter ended on June 30 was $985 million, up from $949 million a year earlier.

Analysts surveyed by Capital IQ expected $987.2 million.

The company expects Q3 adjusted EBITDA of $235 million to $245 million. Analysts polled by Capital IQ expect $238.7 million. The company updated its full-year adjusted EBITDA to a new range of $915 million to $935 million versus the prior outlook of $910 million to $930 million. Analysts polled by Capital IQ expect $921.6 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
McKesson to Buy Controlling Stake in Florida Cancer Specialists' Business Unit for $2.49 Billion
McKesson to Buy Controlling Stake in Florida Cancer Specialists' Business Unit for $2.49 Billion
Aug 29, 2024
10:45 AM EDT, 08/26/2024 (MT Newswires) -- McKesson (MCK) on Monday agreed to purchase a controlling stake in the business and administrative services division of Florida Cancer Specialists & Research Institute, a privately-held operator of cancer clinics, to boost its oncology portfolio. The drug distributor will pay about $2.49 billion in cash for a roughly 70% stake in the Community...
ARS Pharmaceuticals Says EC Approves EURneffy for Emergency Treatment of Allergic Reactions
ARS Pharmaceuticals Says EC Approves EURneffy for Emergency Treatment of Allergic Reactions
Aug 29, 2024
10:45 AM EDT, 08/26/2024 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) said Monday the European Commission has approved EURneffy for the emergency treatment of allergic reactions including anaphylaxis. The adrenaline nasal spray will serve as the first needle-free treatment for severe allergies in the European Union for adults and children weighing 30 kilograms or more, many of whom may...
Liquidity Services Partners With Aaron Industrial Solutions to Sell Unused Industrial Assets in China
Liquidity Services Partners With Aaron Industrial Solutions to Sell Unused Industrial Assets in China
Aug 29, 2024
10:48 AM EDT, 08/26/2024 (MT Newswires) -- Liquidity Services ( LQDT ) said Monday it partnered with Aaron Industrial Solutions to sell unused assets for a firm specializing in industrial gases. The sale features over 60 Sumimoto cryogenic aluminum brazed fin heat exchangers and other equipment that will be available on AllSurplus.com until Aug. 31, Liquidity Services ( LQDT )...
Indivior Says BARDA Makes 1st Order of Opioid Overdose Reversal Nasal Spray
Indivior Says BARDA Makes 1st Order of Opioid Overdose Reversal Nasal Spray
Aug 29, 2024
11:14 AM EDT, 08/26/2024 (MT Newswires) -- Indivior ( INDV ) said Monday that the Biomedical Advanced Research and Development Authority or BARDA has made its first order of Opvee, a nalmefene opioid overdose reversal nasal spray. The company said $8.7 million in Project BioShield designated funding for the initial procurement will be used by BARDA, which is part of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved